Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient
Antiretroviral therapy has changed the history of HIV infection from a lethal disease to a chronic infection, with the emergence of long-term adverse effects. Herein we present a case of a heavily treated HIV-infected man in whom antiretroviral toxicity had been observed. The lopinavir/ritonavir plasma concentrations at standard doses were significantly above the recommended levels. Pharmacogenetic analysis revealed a polymorphism in the DRD3 gene associated with a decrease in the rate of drug metabolism. Additionally, the patient’s low body mass index could have contributed to a greater degree of patient exposure to the drug. After the withdrawal of tenofovir disoproxil and the establishment of individualized protease inhibitor monotherapy at reduced doses, a decrease in the intensity of adverse events was observed, while the clinical outcomes were maintained. The pharmacokinetic-pharmacogenetic analysis was shown to be a tool of huge interest for the management and durability of antiretroviral therapy.
Pure lopinavir and ritonavir compounds were kindly provided by Abbott Laboratories. These substances were used both as standards for the analytical technique validation and as standards in all quantitative determinations.
Compliance with Ethical Standards
No source of funding.
Conflict of interest
Elena López Aspiroz, Salvador Enrique Cabrera Figueroa, María Paz Valverde Merino and Ángel Carracedo declare that they have no conflicts of interest.
All procedures in this study were in accordance with the 1964 Helsinki Declaration; the Ethics Committee of the University Hospital of Salamanca (Spain) approved the study.
Written informed consent was obtained from the patient.
- 7.European AIDS Clinical Society. Guidelines. Clinical management and treatment of HIV-infected adults in Europe. Version 9.1. 2018.Google Scholar
- 8.Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines. Accessed Jan 11 2018.
- 9.Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2018).Google Scholar
- 11.Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009;14:195–201.Google Scholar
- 28.Lubomirov R, Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genom. 2010;20:217–30.Google Scholar
- 34.Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 2016;18:59–68.Google Scholar
- 40.Castronuovo D, Cacopardo B, Pinzone MR, et al. Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci. 2013;17:2413–9.Google Scholar
- 45.Peschl L. Clinical and experimental investigations of the effect of dopamine on haemodynamics and function of kidney and liver (author’s transl). Wien Klin Wochenschr. 1978;86:1–33.Google Scholar
- 50.Lê MP, Chaix ML, Chevret S, et al. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018;73:2120–8.CrossRefGoogle Scholar